Chan, Andrew

Up a level
Export as [feed] RSS
Group by: Date | Item Type | Refereed | No Grouping
Jump to: 2016

2016

Kinner, Markus; Hoepner, Robert; Klotz, Peter; Prehn, Christian; Faissner, Simon; Salmen, Anke; Linker, Ralf A; Gold, Ralf; Chan, Andrew (2016). Immunotherapy Improves Cognitive Function in Secondary Progressive Multiple Sclerosis. CNS neuroscience & therapeutics, 22(12), pp. 1019-1022. Wiley 10.1111/cns.12652

Fox, Robert J; Chan, Andrew; Zhang, Annie; Xiao, James; Levison, Dane; Lewin, James B; Edwards, Michael R; Marantz, Jing L (2016). Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis. Current medical research and opinion, 33(2), pp. 1-23. Informa Healthcare 10.1080/03007995.2016.1248380

Hoepner, Robert; Kolb, Eva M; Dahlhaus, Stefanie; Hellwig, Kerstin; Adams, Ortwin; Kleiter, Ingo; Salmen, Anke; Schneider, Ruth; Lukas, Carsten; Chan, Andrew; Berger, Joseph R; Gold, Ralf (2016). Predictors of severity and functional outcome in natalizumab-associated progressive multifocal leukoencephalopathy. Multiple sclerosis journal, 23(6), pp. 830-835. Sage 10.1177/1352458516667241

Andlauer, Till F M; Buck, Dorothea; Antony, Gisela; Bayas, Antonios; Bechmann, Lukas; Berthele, Achim; Chan, Andrew; Gasperi, Christiane; Gold, Ralf; Graetz, Christiane; Haas, Jürgen; Hecker, Michael; Infante-Duarte, Carmen; Knop, Matthias; Kümpfel, Tania; Limmroth, Volker; Linker, Ralf A; Loleit, Verena; Luessi, Felix; Meuth, Sven G; ... (2016). Novel multiple sclerosis susceptibility loci implicated in epigenetic regulation. Science Advances, 2(6), e1501678. American Association for the Advancement of Science 10.1126/sciadv.1501678

Klotz, L; Berthele, A; Brück, W; Chan, Andrew; Flachenecker, P; Gold, R; Haghikia, A; Hellwig, K; Hemmer, B; Hohlfeld, R; Korn, T; Kümpfel, T; Lang, M; Limmroth, V; Linker, R A; Meier, U; Meuth, S G; Paul, F; Salmen, Anke; Stangel, M; ... (2016). [Monitoring of blood parameters under course-modified MS therapy : Substance-specific relevance and current recommendations for action]. Der Nervenarzt, 87(6), pp. 645-659. Springer 10.1007/s00115-016-0077-1

Sehr, T; Proschmann, U; Thomas, K; Marggraf, M; Straube, E; Reichmann, H; Chan, Andrew; Ziemssen, T (2016). New insights into the pharmacokinetics and pharmacodynamics of natalizumab treatment for patients with multiple sclerosis, obtained from clinical and in vitro studies. Journal of neuroinflammation, 13(1), p. 164. BioMed Central 10.1186/s12974-016-0635-2

Sadovnick, A Dessa; Traboulsee, Anthony L; Bernales, Cecily Q; Ross, Jay P; Forwell, Amanda L; Yee, Irene M; Guillot-Noel, Lena; Fontaine, Bertrand; Cournu-Rebeix, Isabelle; Alcina, Antonio; Fedetz, Maria; Izquierdo, Guillermo; Matesanz, Fuencisla; Hilven, Kelly; Dubois, Bénédicte; Goris, An; Astobiza, Ianire; Alloza, Iraide; Antigüedad, Alfredo; Vandenbroeck, Koen; ... (2016). Analysis of Plasminogen Genetic Variants in Multiple Sclerosis Patients. G3 Genes Genomes Genetics, 6(7), pp. 2073-2079. Genetics Society of America 10.1534/g3.116.030841

Disanto, Giulio; Benkert, Pascal; Lorscheider, Johannes; Mueller, Stefanie; Vehoff, Jochen; Zecca, Chiara; Ramseier, Simon; Achtnichts, Lutz; Findling, Oliver; Nedeltchev, Krassen; Radue, Ernst-Wilhelm; Sprenger, Till; Stippich, Christoph; Derfuss, Tobias; Louvion, Jean-François; Kamm, Christian Philipp; Mattle, Heinrich; Lotter, Christoph; Du Pasquier, Renaud; Schluep, Myriam; ... (2016). The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options. PLoS ONE, 11(3), e0152347. Public Library of Science 10.1371/journal.pone.0152347

Salmen, Anke; von Ahsen, N.; Trampe, A. K.; Hoepner, R.; Plavina, T.; Subramanyam, M.; Kuesters, G.; Gold, R.; Chan, Andrew (2016). Longitudinal analyses of anti-JCV antibody index for risk assessment of progressive multifocal leukoencephalopathy. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2, p. 205521731663000. Sage Publications 10.1177/2055217316630008

Provide Feedback